Literature DB >> 36036290

Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes.

Dafeng Xu1, Yu Wang2, Yonghai Chen1, Jinfang Zheng3.   

Abstract

CD8 + T lymphocytes are immune cells that play a crucial anti-tumor role in the human body, and prognostic value of CD8 + T cell-related regulatory genes in PAAD remains elusive. Data on 179 expression profiles across 13 immune cell datasets were downloaded from the GEO database, and the expression profiles of CD8 + T cell-related genes were obtained using WGCNA. Molecular subtypes based on CD8 + T cell-related genes were constructed using the ConsensusClusterPlus algorithm. Lasso regression analysis was performed to build a 10-gene signature. GSVA was performed to explore the pathways related to these ten genes. The IMvigor210 cohort was used to explore the predictive efficacy of the signature in terms of immunotherapy response. Four hundred and forty-six CD8 + T cell-related genes were obtained. One hundred and nine genes in TCGA and GEO datasets were closely related to the prognosis of patients and were included in the next study. PAAD samples were divided into two subtypes (IC1 and IC2) according to consensus cluster analysis. These two immune subtypes were significantly different in terms of immune checkpoint genes, immune function, and drug treatment response. Additionally, the 10-gene signature constructed based on CD8 + T cell-related genes showed a stable prognostic performance in TCGA and GEO cohorts. Moreover, it served as an independent prognostic factor for patients with PAAD. Furthermore, the 10-gene signature could effectively predict the response to immunotherapy. The immunophenotyping-derived prognostic model based on CD8 T cell-related genes provides a basis for the clinical treatment of pancreatic cancer.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CD8 T cells; Immune checkpoint inhibitor; Immunotyping; Pancreatic cancer; Prognosis

Year:  2022        PMID: 36036290     DOI: 10.1007/s00262-022-03269-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  56 in total

Review 1.  Pancreatic cancer.

Authors:  Audrey Vincent; Joseph Herman; Rich Schulick; Ralph H Hruban; Michael Goggins
Journal:  Lancet       Date:  2011-05-26       Impact factor: 79.321

2.  Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Authors:  Changqing Xie; Austin G Duffy; Gagandeep Brar; Suzanne Fioravanti; Donna Mabry-Hrones; Melissa Walker; Cecilia Monge Bonilla; Bradford J Wood; Deborah E Citrin; Elizabeth M Gil Ramirez; Freddy E Escorcia; Bernadette Redd; Jonathan M Hernandez; Jeremy L Davis; Billel Gasmi; David Kleiner; Seth M Steinberg; Jennifer C Jones; Tim F Greten
Journal:  Clin Cancer Res       Date:  2020-01-29       Impact factor: 12.531

3.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

4.  Pancreatic cancer: why is it so hard to treat?

Authors:  Paul E Oberstein; Kenneth P Olive
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

5.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

Review 6.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

7.  Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

Authors:  Eileen M O'Reilly; Do-Youn Oh; Neesha Dhani; Daniel J Renouf; Myung Ah Lee; Weijing Sun; George Fisher; Aram Hezel; Shao-Chun Chang; Gordana Vlahovic; Osamu Takahashi; Yin Yang; David Fitts; Philip Agop Philip
Journal:  JAMA Oncol       Date:  2019-10-01       Impact factor: 31.777

8.  Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.

Authors:  Elizabeth D Thompson; Hilda L Enriquez; Yang-Xin Fu; Victor H Engelhard
Journal:  J Exp Med       Date:  2010-07-26       Impact factor: 14.307

9.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 10.  Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?

Authors:  Marc Hilmi; Laurent Bartholin; Cindy Neuzillet
Journal:  World J Gastroenterol       Date:  2018-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.